Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INNOHEP vs LOVENOX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.
Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.
Treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism (FDA-approved),Prophylaxis of venous thromboembolism in patients undergoing hip replacement surgery,Prophylaxis of venous thromboembolism in patients undergoing knee replacement surgery,Prophylaxis of venous thromboembolism in abdominal surgery
Treatment of deep vein thrombosis (DVT),Prevention of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with restricted mobility,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Extended treatment of DVT in cancer patients (off-label)
Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.
Terminal half-life 3-4 hours; clinical context: once-daily dosing provides sustained anti-Xa activity.
Terminal half-life: 4.5-7 hours after subcutaneous administration; prolonged in renal impairment (up to 16 hours with Cr Cl <30 m L/min), requiring dose adjustment.
Tinzaparin is primarily metabolized in the liver via desulfation and depolymerization, with some involvement of renal excretion of lower molecular weight fragments.
Primarily metabolized in the liver by desulfation and depolymerization to lower molecular weight fragments with reduced anticoagulant activity.
Primarily renal; 40-50% of the dose excreted unchanged in urine; minor biliary/fecal elimination.
Renal: 40-60% as active and inactive fragments via glomerular filtration and tubular secretion; biliary/fecal: minimal, <10%.
90% bound to antithrombin III.
Antithrombin III (ATIII) binding: ~100% (enoxaparin is an ATIII-dependent inhibitor); nonspecific protein binding: negligible (<1%).
0.15-0.25 L/kg; reflects limited extravascular distribution consistent with high protein binding.
Vd: 0.1-0.2 L/kg; confined mainly to intravascular space, with limited extravascular distribution; reflects low tissue penetration.
Subcutaneous: 90-100%.
Subcutaneous: 92-100% (nearly complete).
For Cr Cl 30-50 m L/min: dose reduction by 25%; Cr Cl <30 m L/min: dose reduction by 50% and monitor anti-Xa activity. Alternative: avoid use if Cr Cl <30 m L/min.
For Cr Cl <30 m L/min: treatment dose 1 mg/kg subcutaneously once daily; prophylaxis dose 30 mg subcutaneously once daily. No adjustment for Cr Cl 30-50 m L/min but monitor closely.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: contraindicated.
No specific dosing adjustment recommended for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment due to increased risk of bleeding.
Not recommended for use in children due to lack of safety and efficacy data. Consider alternative low molecular weight heparins with established pediatric dosing.
Prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Treatment: 1 mg/kg subcutaneously every 12 hours. Maximum single dose 120 mg. Weight must be >5 kg.
Elderly patients (age ≥75 years) may have reduced renal function; dose should be based on renal function (see renal adjustment). Caution as increased risk of bleeding, especially with body weight <45 kg. Consider anti-Xa monitoring.
Elderly patients >75 years old: increased risk of bleeding; consider lower doses (e.g., 0.75 mg/kg every 12 hours for treatment) and monitor renal function closely; no specific dose adjustment solely by age but use with caution.
Epidural or spinal hematomas may occur in patients anticoagulated with low molecular weight heparins or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider monitoring for signs and symptoms of neurological impairment and urgent treatment if suspected.
Spinal/epidural hematomas may occur in patients anticoagulated with LMWH or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas can result in long-term or permanent paralysis.
Risk of hemorrhage: monitor for signs of bleeding,Thrombocytopenia: risk of heparin-induced thrombocytopenia (HIT),Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) as exposure may be increased,Do not administer intramuscularly due to risk of hematoma,Monitor anti-factor Xa activity in patients with severe renal impairment, obesity, or during pregnancy
Risk of bleeding, especially with invasive procedures or concomitant use of antiplatelet agents,Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS),Increased risk of spinal/epidural hematoma with neuraxial anesthesia,Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) due to reduced clearance,Monitor for signs of bleeding and thrombocytopenia
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT),Active major bleeding,Known hypersensitivity to tinzaparin, heparin, or pork products,Concurrent use of neuraxial anesthesia or spinal puncture (relative; requires caution),Severe uncontrolled hypertension
Active major bleeding,History of heparin-induced thrombocytopenia (HIT),Hypersensitivity to enoxaparin, heparin, or pork products,Use of indwelling epidural catheter for analgesia or therapy
No specific food interactions. Avoid excessive consumption of vitamin K-rich foods (e.g., leafy greens) if also on warfarin; not required with Innohep alone. Limit alcohol intake as it may increase bleeding risk.
No specific food restrictions; avoid excessive alcohol consumption as it may increase bleeding risk.
Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use during pregnancy only if clearly needed. First trimester: minimal risk. Second and third trimesters: increased risk of bleeding, but no structural teratogenic effects reported.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: No known increased risk of major malformations. Second/Third trimesters: Risk of maternal hemorrhage, placental abruption, and fetal hemorrhage due to anticoagulant effect. Use only if clearly needed.
Tinzaparin is not excreted into breast milk in significant amounts due to high molecular weight. M/P ratio not established; expected to be low. Considered compatible with breastfeeding by most authorities.
Excreted in human milk in negligible amounts; M/P ratio not established. Considered compatible with breastfeeding; monitor infant for signs of bruising or bleeding.
Pregnancy may require dose adjustments due to increased plasma volume and renal clearance. Monitor anti-Xa levels if needed; adjust dose to maintain therapeutic range. No standard dosing algorithm; individualize based on weight and renal function.
Renal blood flow increases during pregnancy, potentially increasing clearance. Dose adjustments may be needed in the third trimester based on anti-Xa monitoring. Standard prophylactic dose: 40 mg SC once daily; therapeutic dose: 1 mg/kg SC q12h. Consider weight-based dosing and monitor anti-Xa levels (target 0.5-1.0 IU/m L for therapeutic, 0.2-0.5 IU/m L for prophylaxis).
Use anti-Xa monitoring in patients with renal impairment (Cr Cl <30 m L/min) or extremes of body weight. Innohep (tinzaparin) has a higher molecular weight than other LMWHs, leading to a longer half-life and potential for accumulation in renal failure. Avoid in patients with heparin-induced thrombocytopenia (HIT) history. Protamine sulfate partially reverses effect (up to 60%). Monitor platelets periodically due to risk of HIT.
Enoxaparin is a low molecular weight heparin (LMWH) with predictable pharmacokinetics, eliminating the need for routine monitoring of anti-Xa activity in most patients. Dosing is based on weight and renal function; adjust for Cr Cl <30 m L/min (e.g., 30 mg once daily for VTE prophylaxis). Protamine sulfate partially reverses anticoagulant effect (60% neutralization). Avoid in patients with history of heparin-induced thrombocytopenia (HIT); check platelet counts every 2-3 days during therapy. Subcutaneous injection technique: administer in lateral abdominal wall, pinch skin, insert needle at 45-90° angle, do not rub site. Spinal/epidural hematoma risk with neuraxial anesthesia — remove indwelling catheter at least 12 hours after last prophylactic dose (24 hours for treatment doses).
Do not stop or change dose without consulting your doctor.,Report any signs of unusual bleeding or bruising, black/tarry stools, or blood in urine.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed.,Use electric razor and soft toothbrush to minimize bleeding risk.,Seek immediate medical help if you experience severe headache, vision changes, or signs of allergic reaction.,Do not rub injection site; rotate sites (abdomen, thigh, upper arm).,Keep a record of injection dates and times.
Inject enoxaparin exactly as prescribed; do not skip doses.,Rotate injection sites (left/right side of abdomen) to reduce bruising.,Do not massage the injection site after administration.,Watch for signs of bleeding: unusual bruising, black/tarry stools, pink/red urine, coughing up blood, or severe headache.,Seek emergency care for sudden back pain, numbness, or leg weakness (possible spinal hematoma).,Tell all healthcare providers you are taking this blood thinner before procedures or surgeries.,Use soft toothbrush and electric razor to minimize bleeding risk.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INNOHEP vs LOVENOX, answered by our medical review team.
INNOHEP is a Low Molecular Weight Heparin that works by Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.. LOVENOX is a Low Molecular Weight Heparin that works by Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INNOHEP and LOVENOX depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INNOHEP is: Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.. The standard adult dose of LOVENOX is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INNOHEP and LOVENOX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INNOHEP is classified as Category C. Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use . LOVENOX is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: No known increased risk of major malformations. Second/Third trimesters: Risk of materna. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.